tbuckley/cabot-search huggingface dataset:
Prediction of Bladder Outcomes after Traumatic Spinal Cord Injury: A Longitudinal Cohort Study
Authors: Chiara Pavese, Marc P. Schneider, Martin Schubert, Armin Curt, Giorgio Scivoletto, Enrico Finazzi-Agrò, Ulrich Mehnert, Doris Maier, Rainer Abel, Frank Röhrich, Norbert Weidner, Rüdiger Rupp, Alfons G. Kessels, Lucas M. Bachmann, Thomas M. Kessler
Journal: PLoS Medicine (2016)

Background Neurogenic bladder dysfunction represents one of the most common and devastating sequelae of traumatic spinal cord injury (SCI). As early prediction of bladder outcomes is essential to counsel patients and to plan neurourological management, we aimed to develop and validate a model to predict urinary continence and complete bladder emptying 1 y after traumatic SCI. Methods and Findings Using multivariate logistic regression analysis from the data of 1,250 patients with traumatic SCI included in the European Multicenter Spinal Cord Injury study, we developed two prediction models of urinary continence and complete bladder emptying 1 y after traumatic SCI and performed an external validation in 111 patients. As predictors, we evaluated age, gender, and all variables of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) and of the Spinal Cord Independence Measure (SCIM). Urinary continence and complete bladder emptying 1 y after SCI were assessed through item 6 of SCIM. The full model relies on lower extremity motor score (LEMS), light-touch sensation in the S3 dermatome of ISNCSI, and SCIM subscale respiration and sphincter management: the area under the receiver operating characteristics curve (aROC) was 0.936 (95% confidence interval [CI]: 0.922–0.951). The simplified model is based on LEMS only: the aROC was 0.912 (95% CI: 0.895–0.930). External validation of the full and simplified models confirmed the excellent predictive power: the aROCs were 0.965 (95% CI: 0.934–0.996) and 0.972 (95% CI 0.943–0.999), respectively. This study is limited by the substantial number of patients with a missing 1-y outcome and by differences between derivation and validation cohort. Conclusions Our study provides two simple and reliable models to predict urinary continence and complete bladder emptying 1 y after traumatic SCI. Early prediction of bladder function might optimize counselling and patient-tailored rehabilitative interventions and improve patient stratification in future clinical trials.
Short-Term Exposure to Urban Air Pollution and Influences on Placental Vascularization Indexes
Authors: Karen Hettfleisch, Lisandra Stein Bernardes, Mariana Azevedo Carvalho, Luciana Duzolina Manfré Pastro, Sandra Elisabete Vieira, Silvia R. D. M. Saldiva, Paulo Saldiva, Rossana Pulcineli Vieira Francisco
Journal: Environmental Health Perspectives (2016)

It has been widely demonstrated that air pollution can affect human health and that certain pollutant gases lead to adverse obstetric outcomes, such as preeclampsia and fetal growth restriction.We evaluated the influence of individual maternal exposure to air pollution on placental volume and vascularization evaluated in the first trimester of pregnancy.This was a cross-sectional study on low-risk pregnant women living in São Paulo, Brazil. The women carried passive personal NO2 and O3 monitors in the week preceding evaluation. We employed the virtual organ computer-aided analysis (VOCAL) technique using three-dimensional power Doppler ultrasound to evaluate placental volume and placental vascular indexes [vascularization index (VI), flow index (FI), and vascularization flow index (VFI)]. We analyzed the influence of pollutant levels on log-transformed placental vascularization and volume using multiple regression models.We evaluated 229 patients. Increased NO2 levels had a significant negative association with log of VI (p = 0.020 and beta = -0.153) and VFI (p = 0.024 and beta = -0.151). NO2 and O3 had no influence on the log of placental volume or FI.NO2, an estimator of primary air pollutants, was significantly associated with diminished VI and VFI in the first trimester of pregnancy.
Depression in alcoholic schizophrenic patients
Authors: K T Brady, T Killeen, P Jarrell
Journal: American Journal of Psychiatry (1993)

Ten alcoholic schizophrenic patients, 10 alcoholic patients, and 10 schizophrenic patients were rated on the Hamilton Rating Scale for Depression at admission to and discharge from a psychiatric hospital. In all three groups there were statistically significant decreases in depression scores by the time of discharge. The presentation and resolution of depressive symptoms in the alcoholic schizophrenic patients closely resembled that in the alcoholic patients.
Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).
Authors: Sharon Wilks, Manuel R. Modiano, Alexander I. Spira, Carlos Becerra, Hyo S. Han, Fadi S. Braiteh, Elisavet Paplomata, Timothy J. Pluard, Donald A. Richards, Joyce O'Shaughnessy, Jackie Walling, Robert S. Fishman, Gabrielle Baker, Suzanne D. Conzen, Rita Nanda
Journal: Journal of Clinical Oncology (2016)

e12550 Background: GR is highly expressed in TNBC and is associated with a poor prognosis in estrogen receptor-negative (ER-) early stage breast cancer. Treatment with MIFE potentiates the effects of chemotherapy (ctx) in TNBC xenografts. Here we describe the results of an ongoing trial including outcomes to date in all patients with GR+ TNBC treated at the recommended Phase 2 dose (RP2D). Objectives: To determine the safety, tolerability, pharmacokinetics (PK) and clinical activity of the MIFE+E combination in pts with GR+ TNBC at the RP2D. Methods: Eligibility: Phase 1, pts with solid tumors; Phase 2, pts with GR+ TNBC; up to 5 prior ctx regimens for advanced disease; ECOG PS 0-1; adequate end-organ function. Design: 3 + 3 dose escalation scheme. After a 7-day lead-in of oral daily MIFE alone, MIFE was continued daily and E was given on days 1 and 8 of a 21-day cycle. Results: 16 pts with metastatic breast cancer were enrolled in Phase 1 (3 with GR+ TNBC). MTD/RP2D was MIFE 300 mg/day + E 1.1 mg/m2. To date, 12 of 20 planned pts with GR+ TNBC have enrolled in Phase 2 and have completed their first assessment. Of 15 pts with TNBC treated at the RP2D (13 GR+, 2 GR status unknown): 1 PR, 7 SD, 7 PD. DLT was uncomplicated neutropenia. Neutropenia occurred in 21/28 total patients (1 Grade [G] 1, 9 G3, 11 G4). Recovery of counts was brisk with growth factor support. Neuropathy was observed in 8 pts (5 G1, 1 G2, 2 G3). Other most common AEs (fatigue, hypokalemia, nausea, alopecia) were mainly G1 or G2; among these, G3/G4 events were limited to fatigue (4 G3) and hypokalemia (2 G3 and 1 G4). There was no impact of MIFE on eribulin PK. Conclusions: MIFE+E is well tolerated and appears to be an active treatment regimen. RP2D is MIFE 300 mg/d + E 1.1mg/m2. Dose-limiting toxicity is neutropenia; the majority of other AEs were mild or moderate. There is no evidence of a PK interaction between MIFE and E. The expansion phase of the study is ongoing. Clinical trial information: NCT02014337.
Higher Than Expected Carrier Frequency Of The Dyskeratosis Congenita RTEL1 p.Arg1264His recessive Founder In Individuals Of Ashkenazi Jewish Ancestry
Authors: Chaim Jalas, Anastasia Fedick, Bari J Ballew, Blanche P Alter, Neelam Giri, Simon Boulton, Kenneth Offit, John Petrini, Nathan Treff, Sharon A Savage
Journal: Blood (2013)
ATCT-13BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL
Authors: Mallika Weant, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, Stevie Threatt, John Sampson, Allan Friedman, Henry Friedman, Annick Desjardins
Journal: Neuro-Oncology (2015)

BACKGROUND: The addition of bevacizumab to RT and temozolomide in newly diagnosed glioblastoma patients was evaluated in two multicenter phase III trials, RTOG0825 and AVAglio, and demonstrated a lack of statistically significant increased survival. In both studies, the majority of patients discontinued bevacizumab at the time of disease progression on bevacizumab. Given encouraging results in other diseases, we evaluated the safety and benefit of incorporating bevacizumab from the time of diagnosis and throughout multiple treatment lines. METHODS: Patients with new diagnosis of WHO grade IV malignant glioma were enrolled after surgical intervention. Patients were initiated on RT and temozolomide (75 mg/m2/day), with bevacizumab (10 mg/kg every 14 days beginning at least 28 days post-operatively). Following RT, patients initiated adjuvant 5-day temozolomide for up to 12 cycles. Bevacizumab was maintained during adjuvant temozolomide, at tumor progression and once patients came off chemotherapy (maintenance phase). RESULTS: All planned 68 patients were enrolled on study. Median age was 55 years and 69% were men. Of the 55 patients who have progressed, 37 (67%) received bevacizumab at progression. We observed a median progression-free survival of 9.8 months [95% confidence interval (CI), 8.8, 13.5 months) and median overall survival of 17.6 months (CI, 14-22.5 months). No study related death occurred. Study related grade 4 toxicities include: thrombocytopenia (n = 7); neutropenia (n = 5); leukopenia (n = 4); and one each of lymphopenia, colonic perforation, sepsis, intracranial hemorrhage, and hypertension. Grade 3 toxicities include: lymphopenia (n = 29); thrombocytopenia (n = 12); neutropenia (n = 10); leukopenia (n = 8); fatigue (n = 10); hypertension (n = 9); proteinuria (n = 6); thromboembolic event (n = 4); nausea (n = 3); acute coronary syndrome (n = 2); allergic reaction (n = 2); infection (n = 5); and one each of anemia, elevated ALT, ventricular tachycardia, optic nerve neuropathy, constipation, oral mucositis, pustular rash, wound infection, cognitive difficulties, stroke, and headaches. CONCLUSION: Continuing bevacizumab beyond progression is tolerable. Subgroup analyses of survival will be presented.
Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455–464
Authors: Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito
Journal: Diabetes Care (2016)

We read with interest the article by Mita et al. (1) in Diabetes Care reporting a beneficial effect of sitagliptin on the progression of carotid intima-media thickening in Japanese patients with type 2 diabetes. This article parallels another article highlighting the prevention of the progression of carotid atherosclerosis by alogliptin in patients with type 2 diabetes (2). The two articles appeared in the same journal ( Diabetes Care ) in 2016, were conducted by the same group, had the same first author, and had the same (almost identical) baseline values of carotid intima-media thickness (IMT) among the patients with diabetes. The two studies also had important differences concerning …
Dynamic Optical Coherence Tomography Capillaroscopy
Authors: Hans Christian Ring, Lotte Themstrup, Christina Alette Banzhaf, Gregor B. E. Jemec, Mette Mogensen
Journal: JAMA Dermatology (2016)

Vasculopathy characterized by functional and structural abnormalities of the microcirculation plays an important role in systemic sclerosis and dermatomyositis. Although there are several advantages in using capillaroscopy, the method does not offer insight on the skin architecture, flow status, or morphology of the deeper dermal vessels. Dynamic optical coherence tomography (D-OCT) is a recently developed OCT technique that enables detection of high-speed changes in back-scattered light caused by moving cells in vessels. The high resolution of OCT enables the detection of the papillary loops.To explore the potential for OCT capillaroscopy of the nailfolds using D-OCT.In this case series study of 4 participants, the nailfolds in 2 patients with systemic sclerosis, 1 patient with dermatomyositis, and a healthy volunteer were scanned using D-OCT. The included patients were all outpatients from the department of dermatology at Bispebjerg Hospital. Data were analyzed from November 2015 to February 2016.Dynamic OCT capillaroscopy revealed a potential for imaging of the capillary morphology, the surrounding skin architecture, and flow status of the capillaries in the nailfold. Moreover, D-OCT quantified evident changes of the blood flow in normal nailfold capillaries after application of nitroglycerine and brimonidine.This case series included 4 adult women. The quantitative measurements of the blood flow in the D-OCT images of the healthy participant showed significant quantitative differences in blood flow before and after application of nitroglycerine (mean difference, 0.035; 95% CI, 0.008-0.061; P = .02) and brimonidine (mean difference, -0.015; 95% CI, -0.082 to -0.039; P < .001). In the dermatomyositis patient, the en face D-OCT images showed a striking detailed Y-shaped dilated capillary correlating with the clinical finding. In the 2 patients with systemic sclerosis, D-OCT depicted megacapillaries, as well as loss of capillaries. Moreover, cross-sectional OCT images demonstrated a characteristic loss of distinct dermo-epidermal junction and more compact dermis with loss of adnexal structures.Compared with conventional capillaroscopy, D-OCT offers second-to-none information on nailfold capillary morphology, overall skin architecture, as well as quantitative data on vascular abnormalities and blood flow in the nailfold in a single scan.
&lt;emph type="ital"&gt;Still Life With Watermelon, Pears, and Grapes&lt;/emph&gt;
Authors: M Therese Southgate
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
Authors: Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, Kensei Yamaguchi, Kei Muro, Hiroyuki Uetake, Takeo Sato, Tomohiro Nishina, Masataka Ikeda, Takeshi Kato, Akiyoshi Kanazawa, Tetsuya Kusumoto, Calvin Chao, Margarita Lopatin, Jayadevi Krishnakumar, Helen Bailey, Kiwamu Akagi, Atsushi Ochiai, Atsushi Ohtsu, Yasuo Ohashi, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2016)

The 12-gene Recurrence Score assay has been validated in resected stage II colon cancer treated with or without chemotherapy and resected stage III disease treated with chemotherapy. This study evaluated the 12-gene Recurrence Score assay for stage II and III colon cancer without chemotherapy to reveal the natural course of recurrence risk in stage III disease.A cohort-sampling design was used. From 1,487 consecutive patients with stage II to III disease who had surgery alone, 630 patients were sampled for inclusion with a 1:2 ratio of recurrence and nonrecurrence. Sampling was stratified by stage (II v III). The assay was performed on formalin-fixed, paraffin-embedded primary cancer tissue. Association of the Recurrence Score result with recurrence-free interval (RFI) was assessed by using weighted Cox proportional hazards regression.Overall, 597 of 630 patients were analyzable-247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for disease stage (hazard ratio for a 25-unit increase in Recurrence Score, 2.05; 95% CI, 1.47 to 2.86; P < .001). With respect to prespecified subgroups, as defined by low (< 30), intermediate (30 to 40), and high (≥ 41) Recurrence Score risk groups, patients with stage II disease in the high-risk group had a 5-year risk of recurrence similar to patients with stage IIIA to IIIB disease in the low-risk group (19% v 20%), whereas patients with stage IIIA to IIIB disease in the high-risk group had a recurrence risk similar to that of patients with stage IIIC disease in the low-risk group (approximately 38%).To our knowledge, this study provides the first validation of the 12-gene Recurrence Score assay in stage III colon cancer without chemotherapy and showed the heterogeneity of recurrence risks in stage III as well as in stage II colon cancer.
An analysis of Respiration-Induced Target Displacement on Four-Dimensional CT and its implications for Gastric Carcinoma Radiotherapy.
Authors: Jun Gong, Anqi Yao, Fuxiang Zhou
Journal: Journal of Clinical Oncology (2015)

e15004 Background: To measure respiration-induced target motion using 4DCT and compare target, target displacement and dosimetric variation of 3D and 4D plans, evaluate the clinical value of 4DCT in gastric cancer radiotherapy. Methods: Datasets from 10 gastric cancer patients with free breathing 4DCT planning scans and 3DCT scans of same treatment position were included in this study. Seven regions of interest (ROIs) were delineated on the CT images of 10 phases of the breath cycle. The displacements of the center of the ROIs in the cranio-caudal (CC), anterior-posterior (AP), and left-right (LR) directions were measured. Three sets of plans (two 3D plan: PTVCalib-3D and PTVEU-3D; one 4D plan: PTV4D) were generated for each patient. The dosimetric parameters and volumes were compared among the three radiotherapy treatment plans in the target and normal tissue. Results: The maximal range of movement based on 4DCT was in the CC direction (P < 0.05). The largest displacement of ROIs in LR, AP and CC directions were 5.5 (2.5) mm (surgical staples), 5.3 (2.7) mm and 7.8 (3.6) mm (hepatic portal region), respectively. There were significant differences in 3D motion vector between different regions (P = 0.001). No significant differences were observed in PTV coverage and dose homogeneity among the three treatment plans (P > 0.05). The mean CTV3D 507.04 (244.76) cm3 was found to be significantly less than the mean ITV4D 605.44 (257.57) cm3 (P = 0.000). The use of the 4D plan significantly reduced the mean PTV volume, and the PTVEU-3D, PTVCalib-3D and PTV4D were 1719.04 (509.35)cm3, 967.87 (384.81)cm3 and 868.87 (318.18)cm3, respectively. 4D plan had lower mean dose and V30 for liver, and also for kidneys and V20 of left kidney (P < 0.05). Compared with EU-3D plan, 4D plan reduced mean liver , left and right kidney dose by 23.2%, 43.5%and 26.1%. The proportional reductions in V30 of liver and V20 of left kidney were 10.8% and 29.7% (P < 0.05). Conclusions: The displacement patterns of targets are different in LR, AP, and CC directions in gastric cancer patients. The use of individualized margins reduced PTV volume and the dose to OARs. Spatial non-uniform margins should be considered for further investigating.
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Authors: Jean Bennett, Jennifer Wellman, Kathleen A Marshall, Sarah McCague, Manzar Ashtari, Julie DiStefano-Pappas, Okan U Elci, Daniel C Chung, Junwei Sun, J Fraser Wright, Dominique R Cross, Puya Aravand, Laura L Cyckowski, Jeannette L Bennicelli, Federico Mingozzi, Alberto Auricchio, Eric A Pierce, Jason Ruggiero, Bart P Leroy, Francesca Simonelli, Katherine A High, Albert M Maguire
Journal: The Lancet (2016)
P1181 : Microbiotal product activation of NLRP3 induces IL-18 synthesis and impairs the epithelial barrier function in reactive cholangiocytes
Authors: M. Marzioni, L. Agostinelli, L. Maroni, S. Saccomanno, E. Mingarelli, C. Rychlicki, S. De Minicis, J.M. Banales, A. Benedetti, G. Svegliati-Baroni
Journal: Journal of Hepatology (2015)
Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome
Authors: Christopher Lemieux, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Sandra Cohen, Jean-Sebastien Delisle, Thomas Kiss, Jean Roy, Silvy Lachance
Journal: Blood (2015)
Pancreas Passage of Rous Sarcoma
Authors: F E POPKEN, C O BAUGHN
Journal: JNCI Journal of the National Cancer Institute (1961)

Serial intracoelomic passage of a strain of Rous sarcoma virus, obtained from Dr. W. Ray Bryan, National Cancer Institute, Bethesda, Maryland, showed the pancreas to be a novel, reliable source of virus for experimental purposes. Intracoelomic injection of pancreas-passed Rous sarcoma virus resulted in a relatively high and reproducible mortality in 8-day-old cockerels within a test period of 22 days. A significant regression in ED50 (P = 0.01) was observed over a series of 30 consecutive passages. The effect of the infection appeared to be a fulminating, ravaging disease, capable of invading and damaging almost any vital organ, with death as the end result.
DRIED HUMAN MILK
Authors: K KAYSER
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Perioperative screening for obstructive sleep apnoea and treatment outcomes: where are the data?
Authors: Salim R. Surani, Joseph Varon
Journal: European Respiratory Journal (2016)

Obstructive sleep apnoea (OSA) is common illness found worldwide, with a reported prevalence ranging from 9% to 24% among the general population [1]. In the USA, approximately 92% of women and 82% of men with moderate-to-severe OSA remain undiagnosed [2]. OSA carries several short- and long-term health consequences. These may range from perioperative complications to the risk of having uncontrolled hypertension, stroke, coronary artery disease and dysrhythmias, to name a few [3–8]. Perioperative obstructive sleep apnoea screening: how should it be evaluated? <http://ow.ly/105cGT>